Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

PHASE2CompletedINTERVENTIONAL
Enrollment

327

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

May 20, 2022

Study Completion Date

February 27, 2023

Conditions
Non-segmental Vitiligo
Interventions
DRUG

AS012

oral administration

DRUG

Placebo

oral administration

Trial Locations (31)

32174

Sun Pharma Site 10, Ormond Beach

33027

Sun Pharma Site 05, Miramar

33175

Sun Pharma Site 04, Miami

33308

Sun Pharma Site 06, Fort Lauderdale

47906

Sun Pharma Site 14, West Lafayette

48084

Sun Pharma Site 07, Troy

70115

Sun Pharma Site 13, New Orleans

70809

Sun Pharma Site 12, Baton Rouge

72022

Sun Pharma Site 02, Bryant

75234

Sun Pharma Site 03, Dallas

78660

Sun Pharma Site 16, Pflugerville

85018

Sun Pharma Site 15, Phoenix

90036

Sun pharma site 30, Los Angeles

94538

Sun Pharma Site 09, Fremont

98012

Sun Pharma Site 11, Mill Creek

160012

Sun Pharma Site 22, Chandigarh

226003

Sun Pharma Site 27, Lucknow

226005

Sun Pharma Site 18, Lucknow

313202

Sun Pharma Site 17, Rājsamand

360005

Sun Pharma Site 28, Rajkot

380016

Sun Pharma Site 19, Ahmedabad

382428

Sun Pharma Site 20, Gandhinagar

411005

Sun Pharma Site 26, Pune

422101

Sun Pharma Site 25, Nashik

431001

Sun Pharma Site 21, Aurangabad

560074

Sun Pharma Site 23, Bangalore

570001

Sun PharmaSite 24, Mysuru

33511.

Sun Pharma Site 01, Brandon

02111

Sun pharma site 31, Boston

02818

Sun Pharma Site 29, East Greenwich

02886

Sun Pharma Site 08, Warwick

All Listed Sponsors
lead

Ache Laboratorios Farmaceuticos S.A.

INDUSTRY